CORT CORCEPT THERAPEUTICS INC Insider Trading

CEO Joseph K Belanoff sold 12,837 shares of CORT at $69.74 under scheduled 10b5-1 plan adopted 2024-11-26

Joseph K Belanoff, Chief Executive Officer, sold 12,837 shares (12.8K shares) of CORCEPT THERAPEUTICS INC (CORT) at $69.74 on 2026-06-01 for a total value of $895,252.38 ($895.3K), reducing his holdings from 2,578,326 shares (2.58M shares) to 2,565,489 shares (2.57M shares), a reduction of -0.5% vs pre-transaction holdings. This sale was part of a pre-arranged 10b5-1 trading plan adopted on 2024-11-26, meaning it was scheduled and not discretionary. At the same ticker, Belanoff's prior five trades show mixed performance: recent sells on 2026-05-01 and 2026-03-25 were followed by positive 30-day returns of +38.7% and negative returns of -8.0% respectively, while earlier sales in late 2025 predominantly resulted in negative 90-day returns (-55.2%, -45.2%, and -46.4%). The company reports a net loss of $-31.8M on revenue of $164.9M, with a P/E ratio of 161.82, reflecting a highly valued unprofitable company; the CEO's substantial remaining stake of 2.57M shares demonstrates continued material alignment with shareholder interests despite the liquidation.

Sean Maduck sells 75,000 shares (89.3% of holdings) for $4.9M under 10b5-1 plan at $65.59 avg; stock now +49.2% in 30 days

Sean Maduck executed 2 separate sales totaling 75,000 shares for $4,918,943.74 on 2026-05-27 under a pre-arranged 10b5-1 trading plan adopted on 2025-12-08, reducing his non-derivative holdings from 83,977 shares to 8,977 shares. The sales occurred at blended average price of $65.59; CORT stock has since moved to $69.49 (current price), representing a +49.2% 30-day change from the transaction date. This transaction is scheduled rather than discretionary per the 10b5-1 plan flag. Maduck retains 166,986 shares through stock option holdings (Table II), meaning his overall economic position extends beyond the non-derivative shares sold. His prior open-market history across all tickers shows an average 90-day return of -13.4% following 20 prior sells, while his same-ticker history at CORT over 5 prior trades shows mixed results: the most recent prior sale on 2025-12-01 experienced a -56.2% 30-day decline, though earlier sales at this ticker showed smaller 30-day reversals.

Corcept CDO exercises options and immediately sells 20k shares; stock down sharply from highs as company posts recent quarterly loss.

William Guyer, Chief Development Officer, exercised stock options and sold the full grant on the same day—a pattern that mirrors his trading history of selling Corcept stock but breaks from his pure-sell track record with an accompanying option exercise. The stock has retreated notably from its recent highs, even as the company reports growing annual revenue and remains profitable on a full-year basis; however, the most recent quarter showed a net loss, signaling operational challenges. Guyer's prior sales in this stock produced mixed timing outcomes: while three trades saw subsequent share price declines (well-timed exits), two others saw the stock rise after the sale, indicating his previous exits from Corcept have not consistently preceded major declines. This current exercise-and-sell occurs in a stock trading well below its peak and follows a period of near-term strength, making it a standard liquidity event rather than a signal of deep insider concern about the company's direction.

CORT CEO sells ~$2M in stock as company navigates recent earnings miss and valuation compression

CEO Joseph Belanoff sold a modest 1.4% of his holdings for roughly $2 million, which alone would be routine. However, the timing reveals an important inflection point: the company delivered a negative earnings surprise last quarter while the stock has nonetheless recovered significantly from its lows and remains well below its peak. Belanoff's sale during a period of near-term weakness in fundamentals—despite the stock's recent 90-day climb—suggests he may be taking profits on the bounce rather than betting on further upside. The company remains profitable and growing revenue year-over-year, but the latest quarter's earnings miss undercuts the growth narrative that likely justified the stock's valuation during its earlier run. This is not a panicked exit; it's a disciplined trim by a leader who may be signaling that current valuations offer a reasonable exit window after weakness.